Bios Partners
VC Fund
Fort Worth, United States
Bios Partners Is A Venture Capital Firm Based In Dallas/Ft. Worth Focused On Investment In Innovative Early-Stage And Growth-Stage Biotech And Medical Device Companies.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 67%
- Fund size:
- $3.3M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Bios Partners invests in
Health CareBiotechnologyTherapeuticsMedicalBiopharma
Stages Bios Partners invests in
Series ASeries BSeries CSeedSeries D
Countries Bios Partners invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Fletcher
|
|||
|
Stella Robertson
|
|||
Travis Whitfill
|
|||
2 more contacts available
Investment Focus
Industry
- Health Care 9 (50%)
- Biotechnology 9 (50%)
- Therapeutics 8 (44%)
- Medical 3 (17%)
- Biopharma 3 (17%)
Stage
- Series A 5 (28%)
- Series B 5 (28%)
- Series C 2 (11%)
- Seed 1 (6%)
- Series D 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Aaron Fletcher
Founder & General Partner
|
Founder & General Partner | Total investments: 0 | Find email | |
|
Stella Robertson
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 2 | Find email | |
|
Travis Whitfill
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $65M / Series D / Sep 13, 2024 | |
Rein Therapeutics
|
Rein Therapeutics is a biopharmaceutical company that is developing therapies for pulmonary and fibrotic diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis, LTI-01 for pleural effusion, and early programs for cystic fibrosis and systemic fibrosis using peptide and proenzyme approaches. | $18M / Post-IPO Equity / Oct 31, 2023 | |
|
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $15M / Series C / Mar 08, 2023 | |
Opus Genetics
|
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The company's pipeline includes gene therapies based on adeno-associated virus (AAV) aimed at treating inherited retinal conditionssuch as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its leading candidate, OPGx-LCA5, is currently in a Phase 1/2 trial for mutations related to LCA5 and has displayed promising early outcomes. Other initiatives encompass OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration, as well as a small molecule therapy for diabetic retinopathy that is ready for Phase 3, which has been developed under a Special Protocol Assessment with the FDA. | $19M / Seed / Sep 22, 2021 | |
|
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $46.9M / Series B / Dec 22, 2020 | |
Azitra
|
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory,is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. | $17M / Series B / Oct 15, 2020 | |
Actuate Therapeutics
|
Actuate Therapeutics provides advancing research to treatment of high impact cancers and neurodegenerative diseases.Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.Actuate was foundedin 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3β, based on intellectual capital developed in the laboratories of Dr. Alan Kozikowski at the University of Illinois-Chicago and the Center for Developmental Therapeutics at Northwestern University.The company is led by a senior management and scientific team with decades of pharmaceutical industry experience leading successful discovery, development, and commercialization of new therapeutic agents and health related technologies.We are currently advancing our lead molecule, 9-ING-41, towards the clinic in 2017. Our competitive analysis shows 9-ING-41 to be Best in Class. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult to treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive. | $6.5M / Series B / Nov 12, 2019 | |
|
Azitra
|
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory,is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. | $14M / Series A / Oct 15, 2019 | |
Trefoil Therapeutics
|
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and causea significant amount of preventable blindness throughout the world.Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering.The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition. | $28M / Series A / Jul 16, 2019 | |
Lung Therapeutics
|
Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a debilitating condition where fluid has built up in the chest cavity surrounding the lungs andfibrinous scar tissue in the pleural cavity blocks fluid drainage. Their first product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. By clearing the fibrinous buildup pharmaceutically, the clinical pathway for these patients is significantly improved, enabling simple draining of pleural fluid without surgery. Their longer-term efforts will target improvement of clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis and other disease conditions. | $36M / Series C / Jun 04, 2019 | |
| See all 18 investments → | |||
Co-Investors
Connecticut Innovations
3 deals together
DEFTA Partners
3 deals together
ExSight Ventures
3 deals together
Biosciences Research and Commercialization Center (BRCC)
2 deals together
Capital Community Angel Investors
2 deals together
InFocus Capital Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Bios Partners invest in?
Bios Partners invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bios Partners?
Public channels for Bios Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bios Partners?
The team at Bios Partners includes Aaron Fletcher (Founder & General Partner), Stella Robertson (Co-Founder & Partner) and Travis Whitfill (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
